trial

Brexpiprazole in Patients With Schizophrenia

NCTId NCT01810783
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 210 (actual)
Sponsored by H. Lundbeck A/S
Primary completion 2015-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
210 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2013-07
Primary completion
2015-12
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Brexpiprazole (Rexulti)

Sponsors

H. Lundbeck A/SLead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.Collaborator

Sites

48 total
Anaheim, United StatesCerritos, United StatesEscondido, United StatesGarden Grove, United StatesLong Beach, United StatesSan Diego, United StatesWashington D.C., United StatesKissimmee, United StatesNorth Miami, United StatesLake Charles, United StatesSt Louis, United StatesCedarhurst, United States

Linked catalysts

1
Brexpiprazole in Patients With Schizophrenia — primary completion2015-12

Facts & assertions

4 sourced
Enrollment
210
Phase
PHASE3
Primary Completion Date
2015-12
Status
COMPLETED
relationships
The graph out of here
drug
Brexpiprazole (Rexulti)
drug
lead_sponsor
H. Lundbeck A/S
company
collaborator
Otsuka Pharmaceutical Development & Commercialization, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication